Printer Friendly

CytoSorbents, TekMed Ink Australia, New Zealand Distribution Deal.

M2 PHARMA-July 23, 2015-CytoSorbents, TekMed Ink Australia, New Zealand Distribution Deal

(C)2015 M2 COMMUNICATIONS

US-based immunotherapy company CytoSorbents Corp. (NASDAQ: CTSO) has inked an exclusive distribution agreement with TekMed Pty Ltd, a provider of dialysis equipment, vascular access devices, and disposables to the acute and chronic healthcare markets in Australia and New Zealand, the company said on Thursday.

This multi-year agreement includes all critical care and cardiac surgery applications in Australia and New Zealand, and is subject to annual minimum purchases of CytoSorb to maintain exclusivity.

According to the Australian Institute of Health and Welfare, in 2011-12, there were 1,345 hospitals in Australia, of which 736 were public acute care hospitals and 285 were private hospitals.

New Zealand has approximately 220 hospitals. Healthcare is insured by a combination of both government funded Medicare as well as overlapping private insurance.

CytoSorbents' expansion into Australia and New Zealand makes CytoSorb available, with registration, to patients in need in 31 countries worldwide.

TekMed provides medical products to the Australian and New Zealand health care markets. Products include blood purification for the ICU, vascular access for Renal and Interventional Radiology, and therapy chairs for Renal and Oncology.

CytoSorbents is a critical care focused immunotherapy company using blood purification to control severe inflammation, with the goal of preventing or treating multiple organ failure in life-threatening illnesses.

CytoSorb, the company's flagship product, is approved in the European Union with distribution in 31 countries around the world, as an extracorporeal cytokine filter, designed to reduce the "cytokine storm" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2015 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jul 23, 2015
Words:288
Previous Article:China's Tucsen Launches 90% QE Scientific CMOS Camera.
Next Article:Tract Therapeutics completes first-in-human Phase I trial to study patient's own immune system cells in kidney transplant recipients.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters